State-owned Liaoning antibiotics and amino-acid API maker, one of China's earliest large-scale pharmaceutical manufacturers.
State-owned Liaoning antibiotics and amino-acid API maker, one of China's earliest large-scale pharmaceutical manufacturers.
Sells antibiotic and amino-acid ingredients in bulk to formulators and hospitals, so profit depends on global ingredient prices and plant utilisation rather than branding. State ownership gives it scale from the planned-economy era but little pricing power.
In one line: A Chinese state-owned legacy antibiotics/amino-acid maker.
Moat: none (scale). Legacy state-owned scale in commodity APIs without a differentiated product line.
Headquarters: Shenyang, China · Founded: 1946 · Employees: 5,727
Size Northeast Pharmaceutical (000597.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $895M, the 2374th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.20 on 18 Nov 2026.
Performance Over six months the shares fell 13.9%, against -24.5% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 19 in its peer set.
Growth Revenue fell 5.8% over the last twelve months (peer median +13.0%); the operating margin is 2.7% (peer median 7.1%).
Valuation It trades at 0.9× enterprise value to sales against a peer median of 4.3× (2nd cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.2 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.45B | CN¥7.04B | CN¥7.47B | CN¥8.16B | CN¥8.73B |
| Revenue growth | — | -6% | -9% | -6% | — |
| Gross profit | CN¥2.59B | CN¥2.48B | CN¥2.74B | CN¥3.14B | CN¥3.23B |
| EBITDA | n/a | CN¥803M | CN¥1.06B | CN¥941M | CN¥782M |
| Net income | CN¥189M | CN¥260M | CN¥410M | CN¥358M | CN¥350M |
| Free cash flow | CN¥837M | CN¥1.01B | CN¥599M | CN¥351M | CN¥864M |
| Capital expenditure | CN¥82.2M | CN¥97.8M | CN¥159M | CN¥235M | CN¥244M |
| Total debt | CN¥4.29B | CN¥3.77B | CN¥5.54B | CN¥6.91B | CN¥5.25B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Northeast Pharmaceutical 000597.SZ | $895M | -14% | -6% | 3% | 0.9× | -7.6% |
| North China Pharmaceutical 600812.SS | $1.08B | -12% | -21% | 5% | 2.4× | 1.0% |
| Shandong Lukang Pharmaceutical 600789.SS | $1.05B | -18% | -7% | 3% | 1.5× | 2.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000597.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.3% | -7.7% | 10th lowest of 21 |
| 6-month return | -13.9% | -24.5% | 6th highest of 19 |
| Distance from 52-week high | -29.2% | -46.6% | 4th highest of 21 |
| Revenue growth (TTM) | -5.8% | +13.0% | 4th lowest of 18 |
| Operating margin | 2.7% | 7.1% | 8th lowest of 18 |
| EV / Sales | 0.9× | 4.3× | 2nd cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -7.6% | 9.1% | 2nd least demanding of 10 |
| Growth delivered (Del g) | -0.7% | +12.4% | 3rd lowest of 10 |
| Hurdle (Req g minus delivered) | -6.9 pp | -4.9 pp | 5th least demanding of 10 |
| ROIC minus cost of capital | +2.2 pp | +1.4 pp | 5th highest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | 0.9× | -7.6% | -0.7% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | 33.4× | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | 3.5× | 19.4% | -6.0% |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | 55.9× | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | 8.5× | n/a | n/a |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 2.6× | -3.7% | +13.8% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 8.3× | 17.7% | +22.7% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 5.2× | 9.1% | +13.4% |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 2.2× | 2.4% | +12.4% |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 7.5× | -10.2% | +18.1% |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | 0.8× | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 4.1× | 31.7% | +4.2% |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | 6.5× | n/a | n/a |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 0.9× | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 1.2× | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | 4.5× | 10.3% | -13.7% |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 1.2× | -4.2% | +10.6% |